Using capillaroscopy to improve diagnosis in patients with undifferentiated connective tissue disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot randomized controlled clinical trial aims to evaluate the impact of capillaroscopy on the management of patients diagnosed with undifferentiated connective tissue disease (UCTD). Conducted at the Quebec university hospital, the study will compare the outcomes of patients receiving capillaroscopy against those receiving usual care over a period of 12 months. The primary objective is to determine how capillaroscopy influences the diagnosis of better characterized connective tissue diseases within the first six months. Secondary objectives include assessing medication changes, healthcare utilization, and lifestyle modifications following the intervention.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Be aged 18 and over;
* Have been diagnosed with undifferentiated connective tissue disease by a rheumatologist;
* Meet the preliminary classification criteria for undifferentiated connective tissue disease: present signs and symptoms suggestive of connective tissue disease, but do not meet the criteria for a connective tissue disease and have a positive antinuclear antibody on at least 2 occasions;
* Have developed the first signs and symptoms of the disease less than 10 years before recruitment.

Exclusion Criteria:

* In the opinion of the clinician, have a health condition that does not allow a delay of six months before carrying out the capillaroscopy;
* Have been diagnosed and/or meet the classification criteria for another connective tissue disease (for example, systemic lupus, etc.);
* Have already performed a capillaroscopy in the past, regardless of the time or the reason;
* Be unable to consent or respond to questionnaires.

Where it's running

• CHU de Quebec-Université Laval
  Québec, Quebec, Canada Recruiting

Study contacts

• Principal investigator: Laetitia Michou, MD PhD — CHU de Quebec (Université Laval)
• Study coordinator: Laetitia Michou, MD PhD
• Email: laetitia.michou@crchudequebec.ulaval.ca
• Phone: 418-525-4444

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Registry and biorepository for rheumatic diseases

  This study is collecting samples and health information from adults with rheumatic diseases at Yale clinics to help researchers learn more about these conditions and improve future treatments.

  Recruiting Yale University · New Haven, Connecticut · NCT04402086

• Therapeutic patient education for adults with obesity and metabolic disorders

  Aimed at adults with obesity, this study tests whether a co-developed therapeutic patient education program is acceptable and feasible to help with daily self-management.

  Recruiting CHU de Quebec-Universite Laval · Québec, Quebec · NCT07668661

• Shorter Salvage Radiotherapy after Prostate Surgery for Recurrent Prostate Cancer

  This study tests whether a shorter, 4-week salvage radiotherapy schedule is as safe and effective as the standard 5-week schedule for men with prostate cancer that has come back after surgery.

  Recruiting CHU de Quebec-Universite Laval · Gatineau, Quebec and 3 other locations · NCT07483658

• Dutasteride to prevent recurrence of low-grade non-muscle invasive bladder cancer

  This will see if taking the oral medicine dutasteride can lower the chance that low-grade non-muscle invasive bladder cancer comes back in adults.

  Recruiting Phase 2 CHU de Quebec-Universite Laval · Québec, Quebec · NCT07420517

• Four-timepoint PET scans with three tracers to map differences between prostate cancer metastases

  This will test whether repeating PET scans with three different tracers can map active, treatment‑resistant versus treatment‑sensitive metastases in men with metastatic castration‑resistant prostate cancer who have at least three metastases.

  Recruiting CHU de Quebec-Universite Laval · Québec, Quebec · NCT07302763

• Gene-modified autologous skin graft (GMEB-SASS) for RDEB

  This trial will try a gene-modified skin graft grown from a patient's own cells to help wounds heal in people with recessive dystrophic epidermolysis bullosa (RDEB).

  Recruiting Phase 1/2 CHU de Quebec-Universite Laval · Toronto, Ontario · NCT07193134

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.